November 30, 2025Frontiers in MicrobiologyOpen Access

Mesenchymal stem cells alleviate pulmonary fibrosis and gut microbiota dysbiosis in systemic sclerosis

View Full Paper

Ask AI

Bookmark

Authors

BNBiao Ni YGYufang Gong BLBin Li

Discussion

Member takes

Implication

Observational analysis revealed mesenchymal stem cells reduced pulmonary fibrosis and improved gut microbiota dysbiosis in systemic sclerosis, suggesting a novel intervention pathway.

Key Points

Mesenchymal stem cells mitigated pulmonary fibrosis and improved gut microbiota dysbiosis in systematic sclerosis.
Transcriptomic analysis indicated key effects related to fatty acid metabolism and signaling pathways.
Metabolomic and transcriptomic effects were linked to changes in Akkermansia muciniphila and microbiota composition.
These findings highlight mesenchymal stem cells as a promising therapeutic target for systemic sclerosis.

Cite This Study

Ni et al. (2025) studied this question.

synapsesocial.com/papers/692b944c1d383f2b2a378c2b https://doi.org/10.3389/fmicb.2025.1635809

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis revealed mesenchymal stem cells reduced pulmonary fibrosis and improved gut microbiota dysbiosis in systemic sclerosis, suggesting a novel intervention pathway.

Mesenchymal stem cells alleviate pulmonary fibrosis and gut microbiota dysbiosis in systemic sclerosis

Discussion

Member takes

Implication

Key Points

Cite This Study

Mesenchymal stem cells alleviate pulmonary fibrosis and gut microbiota dysbiosis in systemic sclerosis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider